Adimmune Corp (4142) - Total Liabilities
Based on the latest financial reports, Adimmune Corp (4142) has total liabilities worth NT$3.53 Billion TWD (≈ $111.13 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Adimmune Corp - Total Liabilities Trend (2007–2024)
This chart illustrates how Adimmune Corp's total liabilities have evolved over time, based on quarterly financial data. See Adimmune Corp current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Adimmune Corp Competitors by Total Liabilities
The table below lists competitors of Adimmune Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ajinomoto Malaysia Bhd
KLSE:2658
|
Malaysia | RM161.97 Million |
|
Zalaris ASA
OL:ZAL
|
Norway | Nkr941.88 Million |
|
SHIPPING CORPORATION OF INDIA LAND
NSE:SCILAL
|
India | Rs5.45 Billion |
|
Coincheck Group N.V. Ordinary Shares
NASDAQ:CNCK
|
USA | $113.97 Billion |
|
Jikai Equipment Manufacturing Co Ltd
SHE:002691
|
China | CN¥295.59 Million |
|
GDEV Inc.
NASDAQ:GDEV
|
USA | $323.68 Million |
|
Libra Insurance Company Ltd
TA:LBRA
|
Israel | ILA1.01 Billion |
|
BT Group Plc
LSE:BT-A
|
UK | GBX38.07 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down Adimmune Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 4142 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adimmune Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adimmune Corp (2007–2024)
The table below shows the annual total liabilities of Adimmune Corp from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$2.92 Billion ≈ $91.99 Million |
-21.23% |
| 2023-12-31 | NT$3.71 Billion ≈ $116.79 Million |
+42.37% |
| 2022-12-31 | NT$2.60 Billion ≈ $82.03 Million |
+65.05% |
| 2021-12-31 | NT$1.58 Billion ≈ $49.70 Million |
-14.48% |
| 2020-12-31 | NT$1.84 Billion ≈ $58.12 Million |
-32.79% |
| 2019-12-31 | NT$2.74 Billion ≈ $86.47 Million |
-28.19% |
| 2018-12-31 | NT$3.82 Billion ≈ $120.41 Million |
+12.53% |
| 2017-12-31 | NT$3.40 Billion ≈ $107.01 Million |
-7.95% |
| 2016-12-31 | NT$3.69 Billion ≈ $116.25 Million |
+110.90% |
| 2015-12-31 | NT$1.75 Billion ≈ $55.12 Million |
+25.90% |
| 2014-12-31 | NT$1.39 Billion ≈ $43.78 Million |
-38.22% |
| 2013-12-31 | NT$2.25 Billion ≈ $70.87 Million |
-0.05% |
| 2012-12-31 | NT$2.25 Billion ≈ $70.91 Million |
+11.97% |
| 2011-12-31 | NT$2.01 Billion ≈ $63.33 Million |
+48.38% |
| 2010-12-31 | NT$1.35 Billion ≈ $42.68 Million |
-30.24% |
| 2009-12-31 | NT$1.94 Billion ≈ $61.18 Million |
+89.58% |
| 2008-12-31 | NT$1.02 Billion ≈ $32.27 Million |
+367.95% |
| 2007-12-31 | NT$218.90 Million ≈ $6.90 Million |
-- |
About Adimmune Corp
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops Adim… Read more